JPMorgan analyst Jessica Fye raised the firm’s price target on Cerevel Therapeutics (CERE) to $45 from $25 and keeps a Neutral rating on the shares to reflect the pending acquisition by AbbVie (ABBV).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- Reviva may be most undervalued in neurology, says H.C. Wainwright
- Cerevel Therapeutics price target raised to $45 from $30 at Wells Fargo
- Cerevel Therapeutics downgraded to Hold from Buy at Jefferies
- Cerevel Therapeutics just downgraded at Stifel, here’s why
